Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Riccardo Bruna, Fabio Benedetti, Carola Boccomini, Caterina Patti, Anna Maria Barbui, Alessandro Pulsoni, Maurizio Musso, Anna Marina Liberati, Guido Gini, Claudia Castellino, Fausto Rossini, Fabio Ciceri, Delia Rota-Scalabrini, Caterina Stelitano, Francesco Di Raimondo, Alessandra Tucci, Liliana Devizzi, Valerio Zoli, Francesco Zallio, Franco NarniAlessandra Dondi, Guido Parvis, Gianpietro Semenzato, Francesco Lanza, Tommasina Perrone, Francesco Angrilli, Atto Billio, Angela Gueli, Barbara Mantoan, Alessandro Rambaldi, Alessandro Massimo Gianni, Paolo Corradini, Roberto Passera, Marco Ladetto, Corrado Tarella

Research output: Contribution to journalArticle

Abstract

A prospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134 high-risk follicular lymphoma patients aged
Original languageEnglish
Pages (from-to)2241-2248
Number of pages8
JournalHaematologica
Volume104
DOIs
Publication statusPublished - Nov 1 2019

    Fingerprint

Cite this

Bruna, R., Benedetti, F., Boccomini, C., Patti, C., Barbui, A. M., Pulsoni, A., Musso, M., Liberati, A. M., Gini, G., Castellino, C., Rossini, F., Ciceri, F., Rota-Scalabrini, D., Stelitano, C., Di Raimondo, F., Tucci, A., Devizzi, L., Zoli, V., Zallio, F., ... Tarella, C. (2019). Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica, 104, 2241-2248. https://doi.org/10.3324/haematol.2018.209932